NCT04341428 - Study to Evaluate the Efficacy and Safety of DWP14012 on Maintaining Healing in Subjects With Healed Erosive Esophagitis | Biotech Hunter

Enrollment

406

Participants

Timeline

Start Date

July 2, 2020

Primary Completion Date

August 30, 2021

Study Completion Date

December 30, 2021

Conditions

Healed Erosive Esophagitis

Interventions

DRUG

DWP14012 20 mg

DWP14012 20 mg, tablet, orally, once daily for up to 24 weeks

DRUG

DWP14012 20 mg placebo

DWP14012 20 mg placebo-matching tablet, orally, once daily for up to 24 weeks

DRUG

Lansoprazole 15 mg

Lansoprazole 15 mg capsule, orally, once daily for up to 24 weeks

DRUG

Lansoprazole 15 mg Placebo

Lansoprazole 15 mg Placebo capsule, orally, once daily for up to 24 weeks

Trial Locations (1)

RECRUITING

The Catholic University of Korea, Yeouido ST. Mary's Hospital, Seoul